Paiva T, Arriaga F, Wauquier A, Lara E, Largo R, Leitao J N
Laboratory of EEG, Centro de Estudos Egas Moniz, INIC, Hospital Santa Maria, Lisboa, Portugal.
Psychopharmacology (Berl). 1988;96(3):395-9. doi: 10.1007/BF00216069.
Ritanserin, a selective and potent serotonin-2 antagonist, is effective in the treatment of a variety of syndromes related to anxiety and depression, including dysthymic disorder. In animals and healthy volunteers, ritanserin specifically increases slow-wave sleep and the hypothesis arises that this effect on sleep may contribute to its therapeutic properties. Therefore, we studied the effects of ritanserin on sleep in a group of dysthymic patients (DSM-III). Polygraphic recording as well as subjective evaluations of the quality of sleep were performed before and at the end of a 4-week period of double-blind medication with either ritanserin (10 mg o.d. in the morning) or placebo. At baseline, patients showed at fragmented and superficial sleep, with low amounts of slow wave sleep. Ritanserin significantly increased Slow Wave Sleep and changed the frequency and distribution of some stage transitions during the night. No other sleep parameters were modified by ritanserin treatment.
利坦色林是一种选择性强效5-羟色胺-2拮抗剂，可有效治疗包括心境恶劣障碍在内的各种与焦虑和抑郁相关的综合征。在动物和健康志愿者中，利坦色林可特异性增加慢波睡眠，由此产生一种假说，即这种对睡眠的作用可能有助于其治疗特性。因此，我们研究了利坦色林对一组心境恶劣障碍患者（DSM-III）睡眠的影响。在为期4周的双盲用药期开始前和结束时，对服用利坦色林（早上口服10毫克）或安慰剂的患者进行了多导睡眠图记录以及睡眠质量的主观评估。在基线时，患者表现出睡眠碎片化且表浅，慢波睡眠量少。利坦色林显著增加了慢波睡眠，并改变了夜间某些睡眠阶段转换的频率和分布。利坦色林治疗未改变其他睡眠参数。
